Antipsychotic Medication in Schizophrenic Patients is Associated with Higher Risks of Developing Bone Fractures and Refractures
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The relationship of antipsychotics and the risk of refracture in treated patients is unclear. The aim of this study is to evaluate the association between prolonged antipsychotic and the incidences of bone fractures and refractures in schizophrenia. Methods: This is a retrospective nested case-control study using Taiwan National Health Insurance Research Database recorded from 2000 to 2005, with cases followed up to end of 2011. Total of 7,842 schizophrenic patients, 3,955 had developed bone fractures were compared with 3,887 control subjects matched in age, sex, and index date. Antipsychotic drug exposure was classified based on the drug type and medication duration. Conditional logistic regression analyses were performed. Odds ratio (OR) and confidence interval (CI) were calculated. Results: We found (after adjustments) higher risks of developing fractures under continued use of typical (OR = 1.70; 95% CI, 1.51−1.91) or atypical antipsychotics (OR = 1.43; 95% CI, 1.28−1.60) were found. Additionally, continued use typical (OR = 1.84; 95% CI, 1.35−2.50) or atypical antipsychotics (OR = 1.44; 95% CI, 1.06−1.95) was positively associated with refracture risks. Moreover, refractures were associated with continuous use of chlorpromazine (one typical antipsychotics, OR = 2.45; 95% CI, 1.14−5.25), and risperidone (OR = 1.48; 95% CI, 1.01−2.16) or zotepine (OR = 2.15; 95% CI, 1.06−4.36) (two atypical antipsychotics). Conclusion: Higher risks of bone fracture and refracture were found in schizophrenia under prolonged medication with typical or atypical antipsychotics. We therefore recommend that clinicians should pay more attention on bone density monitoring for patients using long-term antipsychotics.
Abstract
Objective: The relationship of antipsychotics and the risk of refracture in treated patients is unclear. The aim of this study is to evaluate the association between prolonged antipsychotic and the incidences of bone fractures and refractures in schizophrenia. Methods: This is a retrospective nested case-control study using Taiwan National Health Insurance Research Database recorded from 2000 to 2005, with cases followed up to end of 2011. Total of 7,842 schizophrenic patients, 3,955 had developed bone fractures were compared with 3,887 control subjects matched in age, sex, and index date. Antipsychotic drug exposure was classified based on the drug type and medication duration. Conditional logistic regression analyses were performed. Odds ratio (OR) and confidence interval (CI) were calculated. Results: We found (after adjustments) higher risks of developing fractures under continued use of typical (OR = 1.70; 95% CI, 1.51−1.91) or atypical antipsychotics (OR = 1.43; 95% CI, 1.28−1.60) were found. Additionally, continued use typical (OR = 1.84; 95% CI, 1.35−2.50) or atypical antipsychotics (OR = 1.44; 95% CI, 1.06−1.95) was positively associated with refracture risks. Moreover, refractures were associated with continuous use of chlorpromazine (one typical antipsychotics, OR = 2.45; 95% CI, 1.14−5.25), and risperidone (OR = 1.48; 95% CI, 1.01−2.16) or zotepine (OR = 2.15; 95% CI, 1.06−4.36) (two atypical antipsychotics). Conclusion: Higher risks of bone fracture and refracture were found in schizophrenia under prolonged medication with typical or atypical antipsychotics. We therefore recommend that clinicians should pay more attention on bone density monitoring for patients using long-term antipsychotics.
참고문헌 (20)
- McGrath J, "Schizophrenia: a concise overview of incidence, prevalence, and mortality", Epidemiol Rev, 30, pp.67~76 (2008)
- Kahn RS, "Schizophrenia", Nat Rev Dis Primers, 1, pp.15067~ (2015)
- Yang YH, "Prevalences of schizophrenia, bipolar disorder, and depressive disorders in community between Taiwan and other countries", Taiwan J Psychiatry, 26, pp.77~87 (2018)
- Kishimoto T, "Osteoporosis and fracture risk in people with schizophrenia", Curr Opin Psychiatry, 25, pp.415~429 (2012)
- Fleischhacker WW, "Compliance with antipsychotic drug treatment: influence of side effects", Acta Psychiatr Scand Suppl, 382, pp.11~15 (1994)
- De Hert M, "Relationship between antipsychotic medication, serum prolactin levels and osteopo-rosis", osteoporotic fractures in patients with schizophrenia : a critical literature review, 2016, pp.15, 809~823
- Maguire GA, "Prolactin elevation with antipsychotic medications:mechanisms of action and clinical consequences", J Clin Psychiatry, 63(Suppl 4), pp.56~62 (2002)
- Papola D, "Antipsychotic drug exposure and risk of fracture : a systematic review and meta-analysis of observational studies", Int Clin Psychopharmacol, 33, pp.181~196 (2018)
- Bakken MS, "Antipsychotic drugs and risk of hip fracture in people aged 60and older in Norway", J Am Geriatr Soc, 64, pp.1203~1209 (2016)
- Koponen M, "Antipsychotic use and the risk of hip fracture among community-dwelling persons with Alzheimer’s disease", J Clin Psychiatry, 78, pp.e257~e263 (2017)
- Chu CS, "Association between antipsychotic drug use and cataracts in patients with bipolar disorder : a population-based, nested case-control study", J Affect Disord, 209, pp.86~92 (2017)
- Wu CS, "Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia : a 10-year population-based case-control study", J Clin Psychiatry, 76, pp.1216~1223 (2015)
- Lee SH, "Use of antipsychotics increases the risk of fracture : a systematic review and meta-analysis", Osteoporos Int, 28, pp.1167~1178 (2017)
- Fraser LA, "Falls and fractures with atypical antipsychotic medication use : a population-based cohort study", JAMA Intern Med, 175, pp.450~452 (2015)
- Pouwels S, "Antipsychotic use and the risk of hip", femur fracture : a population-based case-control study, 2009, pp.20, 1499~1506
- Rady A, "Long term use of antipsychotics and adverse effects on bone density", Neuropsychiatry(London), 8, pp.1559~1563 (2018)
- Uchida S, "Osteopenia and the physical function in Japanese patients with schizophrenia", Arch Osteoporos, 12, pp.93~ (2017)
- Rigler SK, "Fracture risk in nursing home residents initiating antipsychotic medications", J Am Geriatr Soc, 61, pp.715~722 (2013)
- Liperoti R, "Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a casecontrol study", J Clin Psychiatry, 68, pp.929~934 (2007)
- Chao CT, "Risk factors for poor functional recovery, mortality, recurrent fractures, and falls among patients participating in a fracture liaison service program", J Am Med Dir Assoc, 20, pp.1129~1136.e1 (2019)